Drugs / rhC1INH
rhC1INH
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03791476 | Jun 2019 → Jan 2022 | kidney failure | University of Wisconsin, Madison | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01359969 | Jan 2012 → Jul 2017 | hereditary angioedema | Pharming Technologies B.V. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01188564 | Jan 2011 → Dec 2012 | hereditary angioedema | Pharming Technologies B.V. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rhC1-INH | “legacy recombinant human C1 esterase inhibitor (rhC1-INH) studies” PMID 42159953 ↗ May 2026 |
| Known as | recombinant human C1 esterase inhibitor | “legacy recombinant human C1 esterase inhibitor (rhC1-INH) studies” PMID 42159953 ↗ May 2026 |
| Known as | recombinant human C1 inhibitor | “recombinant human C1 inhibitor (rhC1INH) at a dose of 50 U/kg when used for the treatment of acute angioedema attacks” NCT01188564 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human C1 inhibitor” NCT01188564 ↗ |
| Route | Intravenous | “receive an intravenous infusion of rhC1INH” NCT01188564 ↗ |